|
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading
Symbol(s)
|
Name of each exchange on
which registered
|
|
|
|
Ordinary share, nominal value £0.002 per share*
|
*
|
The Nasdaq Stock Market LLC
|
Item 8.01 |
Other Events
|
Item 9.01 |
Financial Statements and Exhibits
|
Exhibit No.
|
Description
|
Press Release dated September 14, 2024.
|
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document).
|
IMMUNOCORE HOLDINGS PLC
|
|||
Dated: September 16, 2024
|
By:
|
/s/ Bahija Jallal, Ph.D.
|
|
Name:
|
Bahija Jallal, Ph.D.
|
||
Title:
|
Chief Executive Officer
|